Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00686998 | Phase IIA Study in Patients With Schizophrenia | PHASE2 | COMPLETED | 106 | — | — | May 1, 2008 | Mar 1, 2009 | Mar 29, 2013 | 1 | United States |
PANSS total score, sum of 30 item scores (each on a 0 to 7 scale), assesses positive and negative symptoms of psychopathology on a continuous scale from 0 (the best) to 210 (the worst). Day 28 value was calculated using last observation carried forward (LOCF). Change from baseline was calculated as Day 28 value minus baseline value.
| Arm | Type | Description |
|---|---|---|
| AZD2624 | EXPERIMENTAL | AZD2624 40 mg |
| Olanzapine | OTHER | Olanzapine 15 mg |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo |
| Name | Type | Description |
|---|---|---|
| AZD2624 | DRUG | Oral Suspension |
| Olanzapine | DRUG | PO BID |
| Placebo | DRUG | - |
Inclusion Criteria: * Females of non-childbearing potential * Diagnosis of Schizophrenia Exclusion Criteria: * Clinically relevant disease and /or abnormalities. * Alcohol or substance abuse not in remission * Enrollment in another investigational study within 30 days